Island Pharmaceuticals Ltd Market Cap ($60.92 Million)
Market Cap & Net Worth: Island Pharmaceuticals Ltd (ILA)
Island Pharmaceuticals Ltd market cap. Island Pharmaceuticals Ltd (AU:ILA) has a market capitalization of $60.92 Million (AU$86.10 Million) as of November 12, 2026. Listed on the AU stock exchange, this Australia-based company holds position #20925 globally and #705 in its home market, demonstrating a 18.52% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Island Pharmaceuticals Ltd's stock price AU$0.32 by its total outstanding shares 269052397 (269.05 Million). Also see ILA cash flow conversion for how efficiently the company converts equity into cash flow.
Island Pharmaceuticals Ltd Market Cap History (2021–2026)
Island Pharmaceuticals Ltd market cap history from 2021 to 2026. Data shows change from $48.54 Million to $60.92 Million (-8.49% CAGR). Check Island Pharmaceuticals Ltd share price for real-time trading data and today's change.
Island Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Island Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Island Pharmaceuticals Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
272.17x
Island Pharmaceuticals Ltd's market cap is 272.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $35.22 Million | $11.06K | -$2.83 Million | 3182.90x | N/A |
| 2023 | $18.09 Million | $1.25 Million | -$2.86 Million | 14.45x | N/A |
| 2024 | $32.36 Million | $118.91K | -$3.92 Million | 272.17x | N/A |
Competitor Companies of ILA by Market Capitalization
Companies near Island Pharmaceuticals Ltd in the global market cap rankings as of November 12, 2026. Also see Island Pharmaceuticals Ltd total assets for a full breakdown of the balance sheet.
Key companies related to Island Pharmaceuticals Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #179 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #501 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #179 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.89 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $916.06 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #501 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $250.83 |
Market Capitalization of Island Pharmaceuticals Ltd (2021–2026)
Market capitalization of Island Pharmaceuticals Ltd from 2021 to today. Between 2021 and today, Island Pharmaceuticals Ltd's market cap moved from $48.54 Million to $ 60.92 Million, with a yearly change of -8.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$60.92 Million | -25.58% |
| 2025 | AU$81.86 Million | +152.94% |
| 2024 | AU$32.36 Million | +78.95% |
| 2023 | AU$18.09 Million | -48.65% |
| 2022 | AU$35.22 Million | -27.45% |
| 2021 | AU$48.54 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 11th, 2026 the market cap of Island Pharmaceuticals Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $60.92 Million USD |
| MoneyControl | $60.92 Million USD |
| MarketWatch | $60.92 Million USD |
| marketcap.company | $60.92 Million USD |
| Reuters | $60.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East,… Read more